Internationally renowned company, Newcells Biotech, are using their established expertise in human induced pluripotent stem cell (hiPSC) technology to test their existing model of the human lung epithelium as a platform for
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in place to ensure
Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to continue development of
Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal organoids from human induced pluripotent stem cells (hiPSCs) from Newcastle University. The acquired technology will add to the growing portfolio of proprietary technologies that Newcells
